Convection-enhanced delivery for high-grade glioma.

Journal Article (Journal Article;Review)

Glioblastoma (GBM) is the most common adult primary malignant brain tumor and is associated with a dire prognosis. Despite multi-modality therapies of surgery, radiation, and chemotherapy, its 5-year survival rate is 6.8%. The presence of the blood-brain barrier (BBB) is one factor that has made GBM difficult to treat. Convection-enhanced delivery (CED) is a modality that bypasses the BBB, which allows the intracranial delivery of therapies that would not otherwise cross the BBB and avoids systemic toxicities. This review will summarize prior and ongoing studies and highlights practical considerations related to clinical care to aid providers caring for a high-grade glioma patient being treated with CED. Although not the main scope of this paper, this review also touches upon relevant technical considerations of using CED, an area still under much development.

Full Text

Duke Authors

Cited Authors

  • Kang, JH; Desjardins, A

Published Date

  • February 2022

Published In

Volume / Issue

  • 9 / 1

Start / End Page

  • 24 - 34

PubMed ID

  • 35096401

Pubmed Central ID

  • PMC8789263

International Standard Serial Number (ISSN)

  • 2054-2577

Digital Object Identifier (DOI)

  • 10.1093/nop/npab065


  • eng

Conference Location

  • England